Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 20/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908915 | 0.81 | MAPKAPK2 (0.67) | MAPKAPK2 | |
| SCHEMBL1908920 | 0.80 | MAPKAPK2 (0.62) | MAPKAPK2 | |
| SCHEMBL1908916 | 0.79 | MAPKAPK2 (0.56) | MAPKAPK2 | |
| SCHEMBL3579503 | 0.74 | MAPKAPK2 (0.66) | MAPKAPK2 | |
| SCHEMBL426702 | 0.74 | MAPKAPK2 (0.56) | MAPKAPK2 | |
| SCHEMBL1909008 | 0.72 | MAPKAPK2 (0.53) | MAPKAPK2 | |
| SCHEMBL1908984 | 0.70 | MAPKAPK2 (0.44) | MAPKAPK2 | |
| SCHEMBL28885366 | 0.69 | MAPKAPK2 (0.40) | MAPKAPK2 | |
| SCHEMBL13884134 | 0.69 | MAPKAPK2 (0.80) | MAPKAPK2 | |
| SCHEMBL1909288 | 0.69 | MAPKAPK2 (0.46) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946018-A | S-triazine LSD1 inhibitor and preparation method and application thereof | 郑州大学 | 2024-04-30 | — | — | CN | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | Beta Therapeutics Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| US-20190345143-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2019-11-14 | — | — | US | disclosed |
| EP-3555051-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| EP-3555071-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| EP-3080114-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-10-02 | — | — | EP | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | MAPKAPK2 703/4885 |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | MAPKAPK2 733/4885 |
| US-20190345143-A1 | HEPARANASE INHIBITORS AND USE THEREOF | HPSE, HEXD, ENGASE | MAPKAPK2 2673/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | MAPKAPK2 962/4885 |
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | MAPKAPK2 2673/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | MAPKAPK2 3080/4885 |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | HPSE, HEXD, ENGASE | MAPKAPK2 2107/4885 |
| US-11718609-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | MAPKAPK2 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.